Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

PHASE4CompletedINTERVENTIONAL
Enrollment

37,673

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
TyphoidParatyphoid Fever
Interventions
BIOLOGICAL

Typhoid Vi vaccine

single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)

BIOLOGICAL

Hepatitis A vaccine

720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults

Trial Locations (1)

Unknown

National Institute of Cholera and Enteric Diseases, Kolkata

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Cholera and Enteric Diseases, India

OTHER

collaborator

Wellcome Trust

OTHER

collaborator

University of Western Ontario, Canada

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

International Vaccine Institute

OTHER